Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis.

Abstract

OBJECTIVE:

This integrated analysis evaluates the efficacy and safety of voclosporin, a novel calcineurin inhibitor, at 23.7 mg twice daily in combination with mycophenolate mofetil (MMF) and oral glucocorticoids in lupus nephritis (LN) using pooled data from two large phase II and phase III clinical trials. The purpose was to expand the pool of patients for safety analyses and to increase power for efficacy analyses in patient subpopulations.

METHODS:

Aurinia Urinary Protein Reduction in Active Lupus with Voclosporin (AURA-LV) (phase II) and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA 1) (phase III) were randomized, placebo-controlled, double-blind trials with similar designs and end points comparing voclosporin to control in combination with MMF and oral glucocorticoids for the treatment of LN. The primary efficacy outcome of the integrated analysis was complete renal response (CRR) at approximately one year (Week 48 data from AURA-LV and Week 52 from AURORA 1). Safety was assessed throughout the trials.

RESULTS:

Overall, 534 patients (268 voclosporin; 266 control) were included in the integrated analysis. Significantly more patients achieved a CRR at one year in the voclosporin group than in the control group (43.7% vs. 23.3%; OR 2.76; 95% CI 1.88, 4.05 P < 0.0001). The incidence of adverse events (AEs) was similar (91.4% voclosporin; 87.2% control). Most AEs were mild to moderate in severity; the most commonly reported AEs were classified as infections and infestations (62.2% voclosporin; 54.9% control) and gastrointestinal disorders (45.3% voclosporin; 35.3% placebo). No new or unexpected safety signals were detected.

CONCLUSIONS:

This integrated analysis demonstrates the efficacy and safety of voclosporin in the treatment of LN across the diverse racial and ethnic groups studied.

• Authors: Cristina Arriens, Y K Onno Teng, Ellen M Ginzler, Samir V Parikh, Anca D Askanase, Amit Saxena, Keisha Gibson, Dawn J Caster, Tatsuya Atsumi, Laura Lisk, Simrat Randhawa, Rashieda Gluck, Neil Solomons, Robert B Huizinga
• Journal: Arthritis care & research (Arthritis Care Res (Hoboken)) Vol. 75 Issue 7 Pg. 1399-1408 (07 2023) ISSN: 2151-4658 [Electronic] United States
• PMID: 36039949 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Chemical References

• Glucocorticoids
• Immunosuppressive Agents
• Mycophenolic Acid
• voclosporin

Topics

• Humans
• Glucocorticoids (therapeutic use)
• Immunosuppressive Agents (adverse effects)
• Lupus Nephritis (diagnosis, drug therapy)
• Mycophenolic Acid (therapeutic use)
• Treatment Outcome
• Clinical Trials as Topic